DICE Therapeutics (DICE) Stock Price, News & Analysis

Company Overview

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $47.55 to $47.55
• 50-Day Range: $46.62 to $47.55
• 52-Week Range: $15.08 to $47.90
• Volume: N/A
• Average Volume: 1.03 million shs
• Market Capitalization: $2.27 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DICE Stock Analysis - Frequently Asked Questions

How were DICE Therapeutics' earnings last quarter?

DICE Therapeutics, Inc. (NASDAQ:DICE) announced its quarterly earnings data on Friday, November, 12th. The company reported ($2.30) EPS for the quarter, missing the consensus estimate of ($0.53) by $1.77.

When did DICE Therapeutics IPO?

DICE Therapeutics (DICE) raised $160 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share.

What other stocks do shareholders of DICE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DICE Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Honeywell International (HON), HubSpot (HUBS), Walt Disney (DIS) and Bank of America (BAC).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:DICE
• CIK: 1645569
• Web: www.dicemolecules.com
• Phone: 650-566-1420
• Fax: N/A
• Employees: 71
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.89 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -22.01%
• Return on Assets: -20.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.88
• Quick Ratio: 32.44

Sales & Book Value

• Annual Sales: $1.13 million
• Price / Sales: 2,008.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.86 per share
• Price / Book: 4.38

Miscellaneous

• Outstanding Shares: 47,731,000
• Free Float: 45,392,000
• Market Cap: $2.27 billion
• Optionable: Not Optionable
• Beta: 1.03